Supply Chain

Here are six articles published by Becker's Hospital Review in the last week, featuring Cleveland Clinic's five-step strategy to address rising drug prices and the counterintuitive economic argument favoring price-gouging during a natural disaster, among other topics.

Bayer on Thursday earned accelerated approval from the Food and Drug Administration for its cancer drug Aliqopa.

Israel-based Teva Pharmaceuticals will sell Paragard, its hormone-free intrauterine device, to Pleasanton, Calif.-based Cooper Companies for $1.1 billion, according to Bloomberg.

Pfizer on Sept. 1 earned Food and Drug Administration approval for its acute myeloid leukemia drug Mylotarg.

U.S. hospitals could lower annual supply expenses by about $23 billion in total by improving supply chain processes and adjusting product use, according to a recent report from Navigant.

Numerous cancer physicians who promote medications on Twitter and receive payments from drugmakers rarely acknowledge the conflict of interest, according to a study published in The Lancet Haematology.

  The U.S. Department of Homeland Security issued a warning Sept. 7 notifying health facilities of potential security flaws in several versions of the MedFusion 4000 Wireless Syringe Infusion Pump manufactured by Plymouth, Mass.-based Smiths Medical.

Cleveland Clinic pharmacists and physicians developed a strategy to limit the financial impact of rising drug prices for two common heart medications, saving the hospital an estimated $8.5 million over the span of two years, according to a case study…

More than 8,000 complaints have been made to the Florida attorney general's office over price spikes for items like food, gas and ice following Hurricane Irma. While most Americans scorn companies for raising prices after a natural disaster, some economists…

Alexion Pharmaceuticals plans to lay off 20 percent of its global workforce as part of its corporate strategy advancement plan, which the company released Tuesday.